Dawn Biopharma

Today we announced a $89 million Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors. We are thrilled to gain further recognition and validation for the trailblazing work our team is conducting in the fields of fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. With the additional capital, we are very well positioned to advance the clinical development of our lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5 (TGFβ1R). The funding further allows us to accelerate the development of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5, and continue the maturation of our pipeline.   #Biotech #Fibrosis #SeriesD

News from our new portfolio company Adcytherix! We participated in the EUR 30mn seed financing round of Adcytherix SAS (Marseille, France) together with Pontifax Venture Capital, RA Capital Management and Dawn Biopharma (a platform controlled by KKR). The company was founded by a team of serial entrepreneurs led by Dr. Jack Elands (CEO). The management team previously founded Emergence Therapeutics, where they were instrumental in shaping its vision and strategy, leading to the acquisition by Eli Lilly and Company last year.

Time for Bambusa to grow super fast. Thanks for a list of very chill investors who stand with me to change the lives of patients who are long overdue for innovative therapeutics.

We are excited to announce that Antag Therapeutics has closed an €80 million Series A financing round, led by Versant Ventures with participation from existing investors Novo Holdings, Longview Ventures, and Export and Investment Fund of Denmark, as well as new investors SR One Capital Management, Dawn Biopharma, Pictet Asset Management. 🎉 This funding will accelerate the clinical development of our lead candidate, AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (#GIPR), targeting obesity management. It will also fuel the expansion of our pipeline of monthly injectable therapies. Preclinical studies of AT-7687 in combination with a GLP-1 receptor agonist have demonstrated the potential to deliver industry leading weight loss alongside significant metabolic benefits. With FDA clearance of our #IND application, we are thrilled to initiate Phase I clinical trials early next year, evaluating AT-7687 as both a monotherapy and in combination with a GLP-1 receptor agonist in obese patients. A huge thank you to our investors for their trust and support in helping us take this important step forward in delivering novel #obesity treatments! Read the full press release on our website, linked in the comments below. #Biotech #GIPRAntagonist #GIP #AntagTherapeutics #Financing

📢 PRESS RELEASE 📢 We are very pleased to announce we’ve completed a $135 million Series B financing!   We are grateful for our current and new investor support and look forward to sharing multiple upcoming company milestones over the next 18-24 months!   Read more about the financing and changes to the board here: https://lnkd.in/e6VCBxDm   #ADC #oncology #biotech #cancer #lifesciences TCGX, TPG, OrbiMed, Venrock, Surveyor Capital, Logos Capital, RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, HealthCap, Gilde Healthcare, Ysios Capital.